Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Orelabrutinib by InnoCare Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Orelabrutinib by InnoCare Pharma for Mantle Cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
Orelabrutinib by InnoCare Pharma for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Orelabrutinib by InnoCare Pharma for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Orelabrutinib is under clinical development by InnoCare Pharma and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...
ICP-248 by InnoCare Pharma for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
ICP-248 is under clinical development by InnoCare Pharma and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
ICP-189 by InnoCare Pharma for Solid Tumor: Likelihood of Approval
ICP-189 is under clinical development by InnoCare Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...